VIM and glioblastoma: Consecutive treatment with Nb79 (anti-VIM) and Nb225 (anti-TUFM) significantly decreased GBM cell survival (U87MG, U251MG, NCH644, and NCH421k), which was found to be the most effective for these GBM cell lines.